12/13/2024
6:52 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
6:53 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/13/2024
4:24 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2024
4:41 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2024
4:02 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024
5:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/11/2024
5:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
12/11/2024
4:31 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Dorsey Brian (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
3:48 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024
10:15 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/09/2024
4:43 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
4:25 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/09/2024
11:38 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144/A | |
12/06/2024
6:15 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2024
4:30 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/05/2024
4:06 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/03/2024
4:25 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
6:01 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
5:22 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024
3:42 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/27/2024
3:11 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/15/2024
2:21 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2024
7:16 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/13/2024
6:02 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/13/2024
6:00 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2024
3:01 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
10:28 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
6:02 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/10/2024
3:27 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
3:28 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/23/2024
3:15 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/19/2024
3:26 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:29 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/19/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:06 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024
3:24 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Do this Before Elon’s Reveal on January 22nd (Ad) Elon’s newest tech could pay you an extra $30,000 a year — while you sleep.
It’s smaller than a quarter but designed to power a $9 trillion AI revolution.
And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. |
09/12/2024
3:25 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
9:31 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/28/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:41 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Thompson Peter A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/23/2024
5:38 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VI LLC (Reporting)
ORBIMED CAPITAL LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:43 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/21/2024
5:47 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:48 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:49 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Scott Kathleen D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
3:18 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/12/2024
6:59 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/18/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
11:07 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Tanimoto Sarina (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/11/2024
4:03 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2024
4:04 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
2:15 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
5:46 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/24/2024
4:06 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dadoo Rajeev (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/24/2024
4:13 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/21/2024
4:00 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
7:47 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/17/2024
5:39 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/13/2024
3:30 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
6:18 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Pratik Shah Living Trust dated June 15, 2011 (Filed by)
| Form SC 13D/A | |
06/11/2024
10:36 AM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024
8:09 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Pratik Shah Living Trust dated June 15, 2011 (Reporting)
Shah Pratik (Reporting)
| Form 4/A | |
06/07/2024
8:11 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/06/2024
3:32 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Pratik Shah Living Trust dated June 15, 2011 (Reporting)
Shah Pratik (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
6:52 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/10/2024
6:01 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
5:57 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
5:59 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
3:08 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/24/2024
5:17 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/24/2024
5:18 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/22/2024
6:22 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/22/2024
6:23 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/17/2024
5:40 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/17/2024
5:42 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2024
4:36 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2024
4:39 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/29/2024
3:14 PM | ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
03/27/2024
6:37 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Do this Before Elon’s Reveal on January 22nd (Ad) Elon’s newest tech could pay you an extra $30,000 a year — while you sleep.
It’s smaller than a quarter but designed to power a $9 trillion AI revolution.
And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. |
03/26/2024
5:47 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/26/2024
5:48 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/21/2024
8:50 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/21/2024
8:51 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/21/2024
4:08 PM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/15/2024
6:52 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
6:55 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/07/2024
11:56 AM | ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/01/2024
7:21 PM | ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
